Next 10 |
2024-07-18 15:02:42 ET More on Exscientia Exscientia: Too Much Pessimism Exscientia plc (EXAI) Q1 2024 Earnings Call Transcript Exscientia: Drug Discovery Platform Attracting Partners And Cash Exscientia to lay off up to 25% of employees; shares down 10% ...
Maximises upside potential of precision-designed GTAEXS617 with purchase of rights from GT Apeiron Monotherapy dose escalation data readout for ELUCIDATE Phase 1/2 trial on track for second half of 2024 Combination dose escalation study starting with HR+/HER2- breast cancer to com...
— State-of-the-art platform, built using Amazon Web Services technologies, integrates generative AI drug design and robotic lab automation to further accelerate Exscientia’s ability to deliver high quality drug candidates at faster speed and lower cost — Exscientia ...
2024-07-08 10:38:54 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Small-cap stocks, typically valued between $300 million and $2 billion, often promise notable growth potential and superior long-term returns. Now, with interest rate cuts on the horizon, inves...
2024-07-03 03:10:00 ET Summary The BioRevolution is a strategy focused on challenging and evolving various aspects of human life, including health care, food production, energy generation and data storage, through biological advancements. At WisdomTree, we have the WisdomTree BioR...
2024-06-10 16:32:01 ET Summary Exscientia is using AI to improve drug discovery and address the low returns on investments in the pharmaceutical industry. While preclinical data generally looks promising, it is too early to know the overall impact of AI on drug discovery. Whil...
2024-06-08 04:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-06 09:08:00 ET Summary We recently rebalanced the WisdomTree Artificial Intelligence & Innovation Index, which is tracked by the WisdomTree Artificial Intelligence & Innovation Fund. The top 10 holdings in WTAI reflect the importance of big platform companies and t...
— AI drug design pioneer John P. Overington, Ph.D., appointed to Chief Technology Officer to maximise strategic technology integration and application — — Maria-Louise Fjällskog, M.D., Ph.D., appointed interim Chief Medical Officer, adding extensive oncology ...
Exscientia plc (Nasdaq: EXAI) today announced that members of Exscientia management will participate in the following upcoming investor conferences in June: Barclays Digital and Disruptive Technology Conference. Panel on Tuesday, June 11, 2024 at 9:45 a.m. BST in London, England G...
News, Short Squeeze, Breakout and More Instantly...
Maximises upside potential of precision-designed GTAEXS617 with purchase of rights from GT Apeiron Monotherapy dose escalation data readout for ELUCIDATE Phase 1/2 trial on track for second half of 2024 Combination dose escalation study starting with HR+/HER2- breast cancer to com...
— State-of-the-art platform, built using Amazon Web Services technologies, integrates generative AI drug design and robotic lab automation to further accelerate Exscientia’s ability to deliver high quality drug candidates at faster speed and lower cost — Exscientia ...